Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.32

-1.7%

12:25 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5817)	3/9/2002 5:59:01 PM
From: Crossy	Read Replies (1) of 52153

re : SCLN To all on this fine thread -- there was a recent newsblip about SCLN pointing to favourable preliminary trial data of their ongoing Phase-3 Zadaxin trial for the treatment of Hepatitis B - biz.yahoo.com now I have this stock - bought it in the $2,40 range - laregely because it was a biotech with Phase 3 trials, a multiproduct pipeline and imagine that, revenues - coupled with low valuation (sub $100m) Does anyone of you have any opinion on SCLN and their prospects here ?? rgrds CROSSY

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next